Bellerophon Therapeutics (NASDAQ: BLPH) reported Q1 EPS of $0.27, $0.75 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.64 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.